乌司他丁在重症急性胰腺炎治疗中的作用分析  

Analysis of the Role of Ulinastatin in the Treatment of Severe Acute Pancreatitis

作　　者：罗金曜 LUO Jinyao(Department of Internal Medicine,Daqing Longnan Hospital,Daqing,Heilongjiang Province,163000 China)

机构地区：[1]大庆龙南医院内科,黑龙江大庆163000

出　　处：《中外医疗》2023年第1期123-126,140,共5页China & Foreign Medical Treatment

摘　　要：目的 探讨重症急性胰腺炎(severe acute pancreatitis, SAP)应用乌司他丁治疗的效果。方法 便利选取2019年10月—2021年2月大庆龙南医院收治的98例SAP患者进行研究,基于单双数分组,对照组给予奥曲肽治疗,观察组在此基础上联用乌司他丁治疗。对比两组用药有效率、症状体征改善时间(腹痛、发热、呕吐、肠鸣音消失时间和白细胞、进食、尿淀粉酶、血淀粉酶正常时间)、肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)、白细胞介素-18(IL-18)水平以及不良反应(恶心呕吐、腹泻、头晕头痛、胸闷心悸)发生率。结果 观察组用药有效率97.96%高于对照组的81.63%,差异有统计学意义(χ^(2)=7.127,P=0.008)。观察组8项症状体征改善时间短于对照组,差异有统计学意义(P<0.05)。用药前,两组TNF-α、IL-10、IL-18水平比较,差异无统计学意义(P>0.05)。用药后,观察组各项炎症因子水平均优于对照组,差异有统计学意义(P<0.05)。两组不良反应(10.20%vs 8.16%)比较,差异无统计学意义(χ^(2)=0.000,P=1.000)。结论 SAP常规治疗期间应用奥曲肽联合乌司他丁治疗,可提升用药效果,调控机体炎症水平,保障用药安全性。Objective To investigate the effect of ulinastatin in the treatment of severe acute pancreatitis(SAP).Methods Conveniently selected 98 SAP patients admitted to Daqing Longnan Hospital from October 2019 to February 2021 for study.Based on odd and even number grouping,the control group was treated with octreotide,while the ob⁃servation group was treated with ulinastatin in combination.Compared the effectiveness of medication,improvement time of symptoms and signs(time for abdominal pain,fever,vomiting,bowel sounds disappeart,and normal time for white blood cells,food intake,urine amylase,and blood amylase),levels of tumor necrosis factor-α(TNF-α),interleu⁃kin-10(IL-10),interleukin-18(IL-18),and incidence of adverse reactions(nausea,vomiting,diarrhea,dizziness,headache,chest tightness,palpitations)between the two groups.Results The effective rate of medication in the obser⁃vation group was 97.96%higher than 81.63%in the control group,and the difference was statistically significant(χ^(2)=7.127,P=0.008).The improvement time of 8 symptoms and signs in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).Before medication,there was no statistically sig⁃nificant difference in the levels of TNF-α,IL-10,and IL-18 between the two groups(P>0.05).After medication,the levels of various inflammatory factors in the observation group were better than those in the control group,and the dif⁃ference was statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(10.20%vs 8.16%)(χ^(2)=0.000,P=1.000).Conclusion During the routine treatment of SAP,the combination of octreotide and ulinastatin can improve the medication effect,regulate the level of inflammation in the body,and ensure the safety of medication.

关 键 词：重症急性胰腺炎 奥曲肽 乌司他丁 用药有效率 炎症因子 不良反应 

分 类 号：R4[医药卫生—临床医学]